Clarity Pharmaceuticals company info

What does Clarity Pharmaceuticals do?
Clarity Pharmaceuticals (ASX:CU6) is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products based on its SAR Technology platform. The company's operations are focused on the development and commercialization of radiopharmaceutical products for the diagnosis and treatment of cancer. Clarity's pipeline covers large cancer indications with significant market opportunities and unmet needs, such as prostate cancer and breast cancer, as well as rare and orphan cancer indications, such as neuroblastoma.
Clarity Pharmaceuticals company media
Company Snapshot

Is Clarity Pharmaceuticals a public or private company?

key
Ownership
Public

How many people does Clarity Pharmaceuticals employ?

people
Employees
43

What sector is Clarity Pharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for Clarity Pharmaceuticals?

location pin
Head Office
Sydney, Australia

What year was Clarity Pharmaceuticals founded?

founded flag
Year Founded
2010
What does Clarity Pharmaceuticals specialise in?
/Biotech /Medtech /Health /Medical /Hospital /Healthcare /Pharmaceuticals

What are the products and/or services of Clarity Pharmaceuticals?

Overview of Clarity Pharmaceuticals offerings
Development and commercialization of radiopharmaceutical products for the diagnosis and treatment of cancer, with a focus on large cancer indications with significant market opportunities and unmet needs, such as prostate cancer and breast cancer, as well as rare and orphan cancer indications, such as neuroblastoma.
Development of SARTATEā„¢, a radiopharmaceutical theranostic for the diagnosis and treatment of neuroblastoma. SARTATEā„¢ is currently in a Phase 3 clinical trial for the treatment of neuroblastoma.
Development of SAR-bisPSMA, a radiopharmaceutical theranostic for the diagnosis and treatment of prostate cancer. SAR-bisPSMA is currently in a Phase 2 clinical trial for the treatment of prostate cancer.
Development of SAR-Bombesin, a radiopharmaceutical theranostic for the diagnosis and treatment of neuroendocrine tumours (NETs). SAR-Bombesin is currently in a Phase 2 clinical trial for the treatment of NETs.
Delivery of radiopharmaceutical products to patients as quickly as possible to make a significant impact on the lives of cancer patients and their families.
Commitment to developing and commercialising innovative radiopharmaceutical products that improve the diagnosis and treatment of cancer.

Who is in the executive team of Clarity Pharmaceuticals?

Clarity Pharmaceuticals leadership team
  • Dr. Alan John Taylor Ph.D.
    Dr. Alan John Taylor Ph.D.
    Executive Chairman
  • Dr. Colin David Biggin Ph.D.
    Dr. Colin David Biggin Ph.D.
    MD, CEO & Executive Director
  • Mr. David K. Green BEc., CA
    Mr. David K. Green BEc., CA
    Chief Financial Officer
  • Mr. Shaemus  Gleason
    Mr. Shaemus Gleason
    Executive Vice President of Operations
  • Dr. Matthew  Harris BSc., M.B.A., Ph.D.
    Dr. Matthew Harris BSc., M.B.A., Ph.D.
    CTO & Director of Technology
  • Dr. Jeffrey  Norenberg
    Dr. Jeffrey Norenberg
    Chief Scientific Officer
  • Michelle  Parker
    Michelle Parker
    Executive Vice President of Global Clinical Operations
  • Mr. Robert  Vickery
    Mr. Robert Vickery
    Company Secretary